Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
29 hedge funds and large institutions have $81.8M invested in Bellerophon Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
18% more capital invested
Capital invested by funds: $69.4M → $81.8M (+$12.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 31 → 29 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$496K |
| 2 |
Renaissance Technologies
New York
|
+$291K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$231K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$141K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$80.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$161K |
| 2 |
TI
Telemetry Investments
New York
|
-$125K |
| 3 |
BlackRock
New York
|
-$30.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$29K |
| 5 |
Millennium Management
New York
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $4K | -$10.6K | -305 | -74% |
|
|
GCM
27
Gables Capital Management
Miami,
Florida
| $3K | +$3.22K | +93 | New |
|
|
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2.42K | – | – | – |
|
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$161K | -4,657 | -99% |
|
|
TSS
30
Two Sigma Securities
New York
| – | -$29K | -931 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | -$12K | -373 | Closed |
|
32
Bank of America
Charlotte,
North Carolina
| – | -$2K | -74 | Closed |
|
|
IA
33
IFP Advisors
Tampa,
Florida
| – | -$3K | -67 | Closed |
|
BLPH Hedge Fund Activity: Q2 2018 in Review
29 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2018, worth a combined $81.8M — up 18% from $69.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BLPH and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was JP Morgan Chase, adding an estimated $496K. The largest seller was Royal Bank of Canada, cutting an estimated $161K.
- 29 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2018, down from 31 in Q1 2018.
- Funds reported $81.8M of Bellerophon Therapeutics, Inc. stock for Q2 2018, up 18% quarter-over-quarter.
- 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2018 and 5 closed out, a net change of -2 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q2 2018 was JP Morgan Chase, an estimated $496K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q2 2018 was Royal Bank of Canada, an estimated $161K sold.
Based on aggregated 13F filings for Q2 2018.